Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SNDX - Syndax Pharmaceuticals Inc

IEX Last Trade
12.57
-0.100   -0.796%

Share volume: 28,766
Last Updated: Fri 27 Dec 2024 05:30:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.39%

PREVIOUS CLOSE
CHG
CHG%
$12.67
-0.10
-0.79%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
29%
Profitability 38%
Dept financing 4%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.80%
1 Month
-20.79%
3 Months
-28.03%
6 Months
-34.26%
1 Year
-38.72%
2 Year
-44.48%
Key data
Stock price
$12.57
P/E Ratio 
-125.39
DAY RANGE
$12.55 - $12.95
EPS 
-$0.23
52 WEEK RANGE
$13.15 - $25.34
52 WEEK CHANGE
-$39.46
MARKET CAP 
1.749 B
YIELD 
N/A
SHARES OUTSTANDING 
85.096 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,740,607
AVERAGE 30 VOLUME 
$2,501,286
Company detail
CEO: Michael A. Metzger
Region: US
Website: syndax.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Syndax Pharmaceuticals, Inc. develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein.

Recent news